According to a retrospective study published this month in the journal Brachytherapy, permanent low-dose-rate (LDR) prostate brachytherapy monotherapy with I-125 has worked well for men with low-and intermediate-risk prostate cancer.
Reducing ADT from 36 to 18 months Improves Quality of Life, Does Not Reduce Survival
A randomized Phase III Trial of outcomes for high-risk prostate cancer patients treated with radiotherapy and either 36 or 18 months of androgen deprivation therapy has found “no difference in survival between the two groups, with the 18-month group experiencing a better quality of life.”
April 29, 2015. Many patients with higher-risk localized prostate cancer are treated with external beam radiation or with brachytherapy (seed implants). A clinical trial conducted by Dr James Miller (right) of Vancouver, Canada has found that patients receiving permanent implant brachytherapy “seeds” plus a boost of radiation have a better chance of long-term survival than those treated with higher dose-escalated external beam radiotherapy but without the implants.